Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Bowen's disease (Squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: Potential applications for this combination of immunotherapy
Autore:
Smith, KJ; Germain, M; Skelton, H;
Indirizzi:
Natl Naval Med Ctr, Dept Dermatol & Pathol, Bethesda, MD 20889 USA Natl Naval Med Ctr Bethesda MD USA 20889 & Pathol, Bethesda, MD 20889 USA Lab Corp Amer, Herndon, VA USA Lab Corp Amer Herndon VA USALab Corp Amer, Herndon, VA USA
Titolo Testata:
DERMATOLOGIC SURGERY
fascicolo: 2, volume: 27, anno: 2001,
pagine: 143 - 146
SICI:
1076-0512(200102)27:2<143:BD(CCI>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNE-RESPONSE MODIFIERS; LANGERHANS CELLS; ANGIOGENESIS; SKIN; CYTOKINE; CANCER; GROWTH; CYCLOOXYGENASE-2; METABOLITES; EXPRESSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Smith, KJ Natl Naval Med Ctr, Dept Dermatol & Pathol, Bethesda, MD 20889 USA Natl Naval Med Ctr Bethesda MD USA 20889 Bethesda, MD 20889 USA
Citazione:
K.J. Smith et al., "Bowen's disease (Squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: Potential applications for this combination of immunotherapy", DERM SURG, 27(2), 2001, pp. 143-146

Abstract

BACKGROUND. Patients with chronic lymphocytic leukemia (CLL) often have a protracted course. However, all these patients are immunosuppressed and mayhave a high incidence of cutaneous malignancies. OBJECTIVE. To determine if combination therapy using topical imiquimod cream 5% and the oral cyclooxygenase (COX) inhibitor are useful in the therapyof squamous cell carcinoma in situ (SCC in situ)/Bowen's disease in patients with long-standing CLL. METHODS. Five CLL patients with head and neck cutaneous SCC in situ, whichmet criteria for Bowen's disease, were treated with topical 5% topical imiquimod cream and an oral COX inhibitor, sulindac 200 mg twice a day. RESULTS. All patients showed clinical resolution and histologic clearing of the tumors after 16 weeks of therapy. CONCLUSION. The local immune modulator, 5% imiquimod, in combination with a COX inhibitor, with its many potential antitumor effects may stimulate the innate and possibly the adaptive immune responses to clear these malignancies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 15:17:43